Long-acting injectable cabotegravir was approved for HIV pre-exposure prophylaxis in late 2021. In this interactive webinar, participants will learn about the effectiveness, advantages, and disadvantages of long-acting injectable cabotegravir as well as the clinical and programmatic steps to incorporate it into practice.
Course Content
Recorded Webinar – Long-Acting Injectable PrEP for HIV: What Health Centers Need to Know
You don't currently have access to this content
Evaluation – Long-Acting Injectable PrEP for HIV: What Health Centers Need to Know
You don't currently have access to this content
